Across TCGA pan-cancer cohorts, DTNB Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DTNB data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher DTNB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DTNB expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
HNSC, UCEC, and KICH are the cancer types where DTNB Mutation most reproducibly stratifies survival.